US pharma firm The Medicines Company (Nasdaq: MDCO) reported a 28.6% fall in quarterly revenue for the first quarter of 2015 on a year-on-year basis.
Worldwide net revenue decreased from $177.2 million in the first quarter of 2014 to $126.5 million in the first quarter of this year, which also compared negatively with the consensus estimate of $138.8 million.
Adjusted net income for the first quarter of 2015 was $5.7 million, or $0.08 per share. In the same quarter last year, The Medicines Company posted earnings per share of $0.33 and adjusted net income of $22.1 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze